Silence Therapeutics set to receive up to £200 million from RNAi collaboration
Silence Therapeutics Plc, which specialises in the technology of RNA-mediated interference for the treatment of disease, has begun a three-year research and development collaboration with AstraZeneca Plc valued at up to £200 million.